

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	<del>1646</del> 1644
Examiner Name	<del>Unassigned</del> Marianne Dibrino/
Attorney Docket Number	60820.000004

Sheet 3 of 10

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	18.	ANDERSEN, M. H. et al., "Phosphorylated Peptides Can Be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL. J. Immunol., 163:3812-3188, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	19.	MCCUTCHEON, M. et al., "A sensitive ELISPOT assay to detect low-frequency human T lymphocytes," J. Immunol. Methods, 210:149-166, 1997	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	20.	PASS, H. A. et al., "Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay," Cancer J. Sci. Am., 4: 316-323, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	21.	BERKE, Z. et al., "Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules," Leukemia, 14:419-426, 2000	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	22.	FALK, K. et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351:290-296, 1991	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	23.	CORNELISON, T. L., "Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment, Curr. Opin. Oncol., 12:466-473, 2000	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	24.	LEE, S. P. et al., "CTL control of EVB in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells," Immunol., 165: 573-582, 2000	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	25.	SWANA, H. S. et al., "Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med., 341: 452-453, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
MD	26.	SALGALLER, M. L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995	<input checked="" type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	<b>10/715,417</b>
		<b>Filing Date</b>	<b>November 19, 2003</b>
		<b>First Named Inventor</b>	<b>Eivind Per Thor STRATEN et al.</b>
		<b>Art Unit</b>	<b>1644</b>
		<b>Examiner Name</b>	<b>Marianne DIBRINO, Ph.D.</b>
<b>Sheet</b>	<b>1 of 2</b>	<b>Attorney Docket Number</b>	<b>60820.000004</b>

U.S. PATENT DOCUMENTS					
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
	1.	WO	2005/049073	06-02-2005	STRATEN et al.		<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS				
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	2.	BERGER et al. Int. J. Cancer, 2004, 111: pages 229-237	<input type="checkbox"/>	<input type="checkbox"/>
	3.	BODEY et al. Anticancer Research 2000, 20: pages 2665-2676	<input type="checkbox"/>	<input type="checkbox"/>
	4.	BOON et al. Ann. Rev. Immunol. 2006, 24: pages 175-208	<input type="checkbox"/>	<input type="checkbox"/>
	5.	CAMPOLI et al., Vaccine. 2002:20, A40-5	<input type="checkbox"/>	<input type="checkbox"/>
	6.	CHAUX et al. J. Immunol. 1999, 163: pages 2928-2936.	<input type="checkbox"/>	<input type="checkbox"/>
	7.	Database EMBL. Baculoviral LAP repeat-containing protein 5 (apoptosis inhibitor survivin) (apoptosis inhibitor 4) (TIAP) 30 May 2000. XP002392545, retrieved from EBI, Database accession no. 070201 May	<input type="checkbox"/>	<input type="checkbox"/>

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through  
citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./